Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan F Assmann

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Circulation. Heart Failure|February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist TrialCarine E Hamo, John F Heitner, Marc A Pfeffer, et al.
European Heart Journal|July 3, 2004
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studiesDavid A Morrow, Elliott M Antman, Sabina A Murphy, et al.
Circulation|September 28, 2005
Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trialHarvey D White, Susan F Assmann, Timothy A Sanborn, et al.
Circulation. Heart Failure|November 20, 2013
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trialAmil M Shah, Sanjiv J Shah, Inder S Anand, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
Circulation. Heart Failure|March 11, 2016
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist TrialEldrin F Lewis, Hae-Young Kim, Brian Claggett, et al.
Transfusion|March 6, 2019
Effects of blood storage age on immune, coagulation, and nitric oxide parameters in transfused patients undergoing cardiac surgeryPhilip C Spinella, Roman M Sniecinski, Felicia Trachtenberg, et al.
Blood|April 28, 2012
Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopeniaCassandra D Josephson, Suzanne Granger, Susan F Assmann, et al.
Journal of the American Heart Association|July 13, 2016
Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) TrialMatthew T Menard, Alik Farber, Susan F Assmann, et al.
American Journal of Hematology|April 8, 2017
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopeniaDavid J Kuter, Barbara A Konkle, Taye H Hamza, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Circulation. Heart Failure|February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist TrialCarine E Hamo, John F Heitner, Marc A Pfeffer, et al.
European Heart Journal|July 3, 2004
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studiesDavid A Morrow, Elliott M Antman, Sabina A Murphy, et al.
Circulation|September 28, 2005
Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trialHarvey D White, Susan F Assmann, Timothy A Sanborn, et al.
Circulation. Heart Failure|November 20, 2013
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trialAmil M Shah, Sanjiv J Shah, Inder S Anand, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
Circulation. Heart Failure|March 11, 2016
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist TrialEldrin F Lewis, Hae-Young Kim, Brian Claggett, et al.
Transfusion|March 6, 2019
Effects of blood storage age on immune, coagulation, and nitric oxide parameters in transfused patients undergoing cardiac surgeryPhilip C Spinella, Roman M Sniecinski, Felicia Trachtenberg, et al.
Blood|April 28, 2012
Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopeniaCassandra D Josephson, Suzanne Granger, Susan F Assmann, et al.
Journal of the American Heart Association|July 13, 2016
Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) TrialMatthew T Menard, Alik Farber, Susan F Assmann, et al.
American Journal of Hematology|April 8, 2017
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopeniaDavid J Kuter, Barbara A Konkle, Taye H Hamza, et al.
Pageof 4